PACB
Pacific Biosciences of California, Inc.Marquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $1.35 | $1.15 | -15% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $1.35 | $1.15 | -15% |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $1.35 | $1.15 | -15% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $1.35 | $1.15 | -15% |
| AQR Capital Management | Q2 2025(8Q snapshot) | 4Q | $1.06 | $1.15 | +8% |
| Point72 Asset Management re-entered | Q3 2025(8Q snapshot) | 3Q | $1.23 | $1.15 | -7% |
| Renaissance Technologies | Q1 2026(8Q snapshot) | 1Q | $1.84 | $1.15 | -38% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Soros Fund Management | Q3 2024 | Q3 2025 | → $1.23 | -9% |
| Viking Global Investors | Q4 2020 | Q4 2021 | → $27 | +71% |
| Glenview Capital | Q1 2020 | Q4 2020 | — | +0% |
| Maverick Capital | Q3 2013 | Q1 2019 | → $7.08 | +91% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at PACIFIC BIOSCIENCES OF CALIFORNIA, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 4, 2026 — the most recent Form 4 on file — not from today.
- Form 40001299130-26-000108Jun 4, 2026
- Form 40001299130-26-000106Jun 4, 2026
- Form 40001299130-26-000104Jun 4, 2026
- Form 40001299130-26-000102Jun 4, 2026
- Form 40001299130-26-000100Jun 4, 2026
- Form 40001299130-26-000098Jun 4, 2026
- Form 40001299130-26-000096Jun 4, 2026
- Form 40001299130-26-000094Jun 4, 2026
- Form 40001856369-26-000010Apr 10, 2026
- Form 40001299130-26-000054Apr 3, 2026
- Form 40001299130-26-000050Mar 5, 2026
- Form 40001299130-26-000043Mar 4, 2026
- Form 40001299130-26-000042Mar 4, 2026
- Form 40001299130-26-000041Mar 4, 2026
- Form 40001299130-26-000040Mar 3, 2026
Fundamentals
XBRL · Pacific Biosciences of California, Inc.Annual figures sourced directly from Pacific Biosciences of California, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for PACIFIC BIOSCIENCES OF CALIFORNIA, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 4, 2026
- 10-QQuarterly reportMay 8, 2026
- 8-KMaterial eventMay 7, 2026
- DEF 14AProxy statementApr 23, 2026
- 8-KMaterial eventMar 6, 2026
- 8-KMaterial eventMar 5, 2026
- 10-KAnnual reportFeb 25, 2026
- 8-KMaterial eventFeb 12, 2026
- 8-KMaterial eventFeb 3, 2026
- 8-KFORM 8-KFeb 2, 2026
- 8-KMaterial eventJan 12, 2026
- 10-QQuarterly reportNov 6, 2025
- 8-KMaterial eventNov 5, 2025
- 10-QQuarterly reportAug 7, 2025
- 8-KMaterial eventAug 7, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| D.E. Shaw | Q1 2026 | open | $1.58 | $1.15 | -27% |
| Point72 Asset Management | Q1 2026 | open | $1.58 | $1.15 | -27% |
| Renaissance Technologies | Q1 2026 | open | $1.84 | $1.15 | -38% |
| Citadel Advisors | Q4 2025 | open | $1.61 | $1.15 | -29% |
| Two Sigma Investments | Q4 2025 | open | $1.61 | $1.15 | -29% |
| D.E. Shaw | Q3 2025 | Q4 2025 | $1.23 | $1.61 | +31% |
| Point72 Asset Management | Q3 2025 | Q4 2025 | $1.23 | $1.61 | +31% |
| AQR Capital Management | Q2 2025 | open | $1.06 | $1.15 | +8% |
| Citadel Advisors | Q3 2024 | Q3 2025 | $1.35 | $1.23 | -9% |
| Soros Fund Management | Q3 2024 | Q3 2025 | $1.35 | $1.23 | -9% |
| Two Sigma Investments | Q3 2024 | Q3 2025 | $1.35 | $1.23 | -9% |
| D.E. Shaw | Q3 2024 | Q4 2024 | $1.35 | $1.86 | +38% |
| Millennium Management | Q3 2024 | open | $1.35 | $1.15 | -15% |
| Viking Global Investors | Q4 2020 | Q4 2021 | $16 | $27 | +71% |
| Glenview Capital | Q1 2020 | Q4 2020 | $0.00 | — | +0% |
| Maverick Capital | Q3 2013 | Q1 2019 | $3.70 | $7.08 | +91% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.